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Pituitary adenomas represent a group of functionally diverse neoplasms with relatively high prevalence in the
general population. Most occur sporadically, but inherited genetic predisposing factors are increasingly recognized.
Familial isolated pituitary adenoma is a recently defined clinical entity, and is characterized by hereditary
presentation of pituitary adenomas in the absence of clinical and genetic features of syndromic disease such as
multiple endocrine neoplasia type 1 and Carney complex. Familial isolated pituitary adenoma is inherited in an
autosomal dominant manner and accounted for approximately 2–3% of pituitary tumors in some series. Germline
mutations in the aryl-hydrocarbon interacting protein gene are identified in around 25% of familial isolated
pituitary adenoma kindreds. Pituitary adenomas with mutations of the aryl-hydrocarbon interacting protein gene
are predominantly somatotropinomas and prolactinomas, but non-functioning adenomas, Cushing disease, and
thyrotropinoma may also occur. These tumors may present as macroadenomas in young patients and are often
relatively difficult to control. Furthermore, recent evidence indicates that aryl-hydrocarbon interacting protein gene
mutations occur in .10% of patients with sporadic macroadenomas that occur before 30 years of age, and in .20%
of children with macroadenomas. Genetic screening for aryl-hydrocarbon interacting protein gene mutations is
warranted in selected high-risk patients who may benefit from early recognition and follow-up.
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INTRODUCTION
Pituitary adenomas are one of the most common
intracranial neoplasms. Questions regarding their preva-
lence in the general population were recently addressed by
a large cross-sectional study in the province of Lie `ge,
Belgium, which revealed 94 cases of pituitary adenomas per
100,000 inhabitants (1). Similar findings were later con-
firmed in Banbury, UK (2). Despite being generally benign,
pituitary adenomas still exert significant influence as they
combine symptoms of hormonal dysfunction with signs of
local compression, and may require complex and costly
management and long-term follow-up. Pituitary adenoma
formation is generally considered to be the result of the
clonal expansion of a single mutated cell (3) and molecular
studies have identified a number of genetic and epigenetic
abnormalities that may have a possible causative or
facilitatory role in pituitary tumorigenesis. These include
somatic mutations in the gsp oncogene, overexpression of
the pituitary tumor transforming gene (PTTG), disruptions
in cell cycle regulation and intracellular signaling pathways
and, rarely, mutations of classic oncogenes (4,5). The vast
majority of pituitary adenomas, however, arise sporadically,
and inherited germline mutations in different genes are few
in number, accounting for approximately 5% of all pituitary
tumors (6). Traditionally, familial pituitary adenomas have
been associated with some multiple neoplasia syndromes,
including multiple endocrine neoplasia type 1 (MEN 1),
Carney complex, and the newly defined multiple endocrine
neoplasia type 4. By the end of the 20th century, however,
only occasional cases of non-syndromic familial pituitary
tumors were reported, mostly acromegaly (7). The first
single-center study to specifically scout for cases of familial
pituitary adenomas unrelated to MEN 1 and Carney
complex was performed in Lie `ge, Belgium in the 1990s,
and led to the identification of an initial cohort of 27 patients
(8). Reports from the same center confirmed the condition as
a new clinical entity, and the term familial isolated pituitary
adenomas (FIPA) was adopted (9–11). Its definition
expanded the search internationally, and by 2011 more
than 200 affected families had been reported (12,13). FIPA is
currently considered to account for around 2–3% of
pituitary adenomas (14).
CLINICAL FEATURES OF PATIENTS WITH FIPA
The syndrome of FIPA is defined as familial presentation
of any type of pituitary adenoma in the absence of clinical
and genetic evidence for MEN 1 and Carney complex
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37(9,11,14,15). Following the initial description of the condi-
tion, the clinical characteristics of a large international
cohort of 64 families comprising more than 140 patients
from 22 tertiary referral centers were reported in 2006 (14).
Genealogical information suggested that FIPA is inherited
in an autosomal dominant pattern with variable penetrance.
Based on the tumor phenotype in the individual families,
FIPA can be divided into two almost equal subgroups:
homogeneous, when all affected family members experience
the same adenoma type, and heterogeneous, with different
pituitary tumors within the family. Prolactinomas and
somatotropinomas comprise more than 70% of all tumors,
and although in heterogeneous FIPA all types of tumors can
be seen, there is at least one prolactin- or growth hormone-
secreting adenoma in almost all affected families. Females
tend to be more frequently affected (62%), which is not
unexpected given the fact that prolactinomas are the most
common phenotype overall. Prolactin-secreting adenomas
comprise 40% of all FIPA tumors, and their characteristics
principally match their sporadic counterparts in terms of
sexual predisposition, age at presentation, and proportion of
microadenomas. In heterogeneous FIPA families, however,
these tumors exhibit more aggressive behavior, with
significantly higher rates of suprasellar expansion and
cavernous sinus invasion compared with sporadic prolacti-
nomas. Growth hormone-secreting adenomas account for
30% of FIPA tumors, and somatoprolactinomas are respon-
sible for another 7%. They are equally distributed between
homogeneous and heterogeneous families but, unlike FIPA
prolactinomas, somatotropinomas are more aggressive
when occurring in a homogeneous setting. In homogeneous
FIPA, acromegaly is usually diagnosed 10 years earlier, with
tumors more frequently displaying extrasellar growth,
compared with heterogeneous relatives and sporadic
populations (14). Acromegaly in patients with FIPA also
appears to respond poorly to somatostatin analog therapy
(16). Non-secreting adenomas, predominantly associated
with heterogeneous families, arise in 13% of patients with
FIPA and are also characterized by more aggressive
evolution, being diagnosed earlier and exhibiting more
invasive properties than sporadic adenomas. Gonado-
tropinomas, corticotropinomas, and thyrotropinomas are
rare, and account for 4%, 4%, and 1% of FIPA tumors,
respectively. They are usually associated with other
adenoma types in heterogeneous families, although indivi-
dual families with homogeneous presentation have been
reported (14). The descendants in FIPA families with
multiple affected generations are diagnosed considerably
earlier than their parents/grandparents.
MOLECULAR GENETICS OF FIPA
The elucidation of the responsible genetic causes of
FIPA started with the identification of loss of hetero-
zygosity in locus 11q13 in relatives with familial acrome-
galy who lacked mutations in the MEN1 gene (17,18).
Separate research for potential genes in a Finnish cohort of
patients with familial pituitary tumors revealed inactivat-
ing mutations in the gene for aryl-hydrocarbon receptor
interacting protein (AIP) (19). The causative role of AIP in
FIPA was confirmed with the discovery of several new
germline mutations in a large series of 73 families (20).
Loss of heterozygosity in tumor tissues suggests a tumor
suppressor function for AIP, but the exact molecular
mechanisms leading to pituitary tumorigenesis are not
known. Homozygous AIP
–/– knockout mice die in the
early embryonic period as a result of severe cardiovascular
abnormalities, suggesting that AIP may play a role in
cardiovascular development (21). Heterozygous AIP
+/–
animals, however, develop a phenotype that is very
similar to human pituitary disease with the majority of
the mice presenting with aggressive somatotropinomas
(22). The AIP gene consists of six exons and codes for a
330-amino-acid protein, the sequence of which is highly
conserved between different species. It shares a structural
homology with immunophilin proteins because of the
presence of a peptidyl-prolyl cis-trans isomerase-like
domain, but does not function as such (23,24). Instead,
AIP takes part in numerous protein–protein interactions,
mediated through its C-terminal, which houses three
tetratricopeptide repeats and a final a-helix. Among the
first identified partners of AIP is the aryl hydrocarbon
receptor (AhR), a ligand-inducible transcription factor that
modulates cellular responses to various xenobiotic toxins,
such as dioxins, as well as some endogenous compounds
such as cAMP (25). In the absence of ligands, the AhR
binds to two molecules of the 90-kDa heat-shock protein,
acting as chaperone, and to AIP and p23 proteins, acting as
co-chaperones, to form a multiprotein complex in the
cytoplasm (26). The activation of this complex by its
xenobiotic ligand results in nuclear translocation, where
AhR binds to the aryl hydrocarbon receptor nuclear
translocator and promotes the transcription of specific
genes coding various drug metabolizing enzymes as well
as other proteins (24). The effect of AIP on the functional
status of AhR is still a matter of debate because conflicting
results have been reported, but it seems that it maintains
the stability of the complex by protecting AhR from
ubiquitin-dependent degradation (27). Reduced AIP levels
in AIP-mutated pituitary adenomas are associated with a
lack of nuclear AhR immunostaining, suggesting that
d o w n - r e g u l a t i o no fA h Rm a yb ei n v o l v e di np i t u i t a r y
t u m o r i g e n e s i s( 2 8 ) .C o n s i s t e n tw i t ht h i sf i n d i n g ,o v e r -
expression of wild-type AIP in pituitary and hepatic cell
cultures slows down cell proliferation (16). AIP is also
thought to interact with two subtypes of phosophodies-
terases: PDE4A5 and PDE2A (29,30). These enzymes
participate in the regulation of numerous signaling
cascades that use cAMP as a second messenger, including
the growth hormone-releasing hormone receptor pathway
in pituitary cells. Disruptions in signal transduction,
which lead to abnormally high cAMP concentrations, are
associated with pituitary hyperplasia and adenoma for-
mation in some conditions, such as Carney complex and
McCune–Albright syndrome (31). AIP binding to PDE4A5
reduces its catalytic activity, and it is not clear if this
interaction plays a role in pituitary tumorigenesis, as loss
of AIP would presumably result in low cAMP levels. The
interaction with PDE2A does not alter the enzyme activity,
and the local reduction of cAMP may impede the nuclear
translocation of the AhR complex (30). Recently, AIP was
shown to interact with the tyrosine kinase receptor,
encoded by the RET proto-oncogene, and the inhibitor of
apoptosis, survivin, and therefore to have a potential role
in cell cycle regulation. Binding to survivin maintains its
stability and promotes cell survival by elevating the anti-
apoptotic threshold. On the other hand, the interaction
with RET prevents the formation of the AIP–survivin
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38complex, resulting in subsequent survivin degradation and
increase in apoptosis (32). These effects, however, are
contrary to the proposed tumor-suppressor role of AIP.
Apart from stabilizing the AhR complex, AIP may also
bind to a set of nuclear receptors including peroxisome
proliferator-activated receptor a, the glucocorticoid recep-
tor, and b-thyroid hormone receptor 1. Furthermore, a role
has been proposed for AIP in virus-induced tumorigenesis
as a potential partner of hepatitis B virus X antigen and
Epstein–Barr virus-encoded nuclear antigen 3 (24).
Over 50 different mutations in the AIP sequence have
been identified in FIPA families from all over the world,
and these mutations are spread through the entire length of
the gene (23,33). Most of them affect the C-terminal end
and the tetratricopeptide repeat motifs supporting their
essential role in AIP function. Nonsense and frameshift
mutations lead to premature stop codons with a resultant
truncated protein, whereas missense mutations tend to
affect the tetratricopeptide repeat domains and the term-
inal a-helix. Whole gene deletions have also been identi-
fied, suggesting the use of a multiple ligation-dependent
probe amplification method for patients with FIPA in
whom sequencing fails to identify abnormalities (34,35,36).
Mutations in codons R304, R271, and R81 have been
reported in independent families with FIPA, indicating
possible hotspots. No genotype–phenotype correlations
have been observed to date in patients with AIP-mutated
FIPA (37).
Mutations in the AIP gene, however, are found in only
approximately 25% of all patients with FIPA, and in 40–50%
of patients in the subgroup with acromegaly from homo-
geneous FIPA families (12). The genetic cause for the rest of
the cases is still unknown, but several other loci, such as
2p16, 3q28, 4q32, 8q12, 19q13, and 21q22, may be involved
in the development of the syndrome although no particular
genes have been identified (38). On the other hand, the
penetrance of AIP mutations is estimated to be approxi-
mately 30% in the largest reported families (15,19,35,39),
suggesting the possible existence of genetic or environ-
mental modifying factors (Figure 1).
CLINICAL CHARACTERISTICS OF PATIENTS WITH
AIP-MUTATED FIPA
Patients with AIP-related pituitary adenomas have also
been shown to exhibit some specific clinical features that
differentiate them from patients with wild-type AIP alleles
(37). In contrast to the overall female predominance in FIPA,
male sex is significantly more common in the subgroup of
patients harboring AIP mutations. All types of pituitary
tumors may occur in association with mutated AIP, but
growth hormone-secreting adenomas largely predominate,
arising in about 80% of patients, and co-secretion of
prolactin is observed in more than 50% of these. A direct
comparison of 75 patients with AIP-mutated somatotropi-
nomas with 232 genetically negative control subjects with
acromegaly revealed that AIP anomalies are associated with
much earlier onset and more aggressive evolution of the
disease (Table 1). Invasive macroadenomas are manifested
in childhood or adolescence in more than half of patients
with AIP mutations, and almost a third of patients with
somatotropinomas present with gigantism. Disease control
is also harder to achieve and maintain, because somatostatin
analogs are less effective for lowering growth hormone and
insulin-like growth factor levels and inducing tumor
shrinkage in acromegaly caused by AIP mutations.
Moreover, these patients have significantly worse long-term
therapeutic control although they frequently undergo
multiple surgeries and radiotherapy. Patients with AIP-
mutated prolactinomas also present with large tumor size
and invasive features. Resistance to dopamine agonists may
be observed in 50% of these, raising the need for surgery
and/or radiotherapy.
CLINICAL IMPLICATIONS AND MANAGEMENT
Similar to the other familial presentations of pituitary
tumors in MEN 1 and Carney complex, the treatment of
FIPA does not differ substantially from the management of
sporadic adenomas in terms of indications and therapeutic
modalities. However, the aggressive nature of FIPA tumors,
especially in patients with AIP mutations requires increa-
sed attention from medical specialists. Detailed physical
Figure 1 - Genealogical tree of a familial isolated pituitary adenoma (FIPA) family with E174 frameshift aryl-hydrocarbon receptor
interacting protein gene (AIP) mutation. Filled black symbols indicate mutation-positive patients with pituitary tumors. (+) symbols
show patients with AIP mutation without clinical, hormonal or radiological evidence for pituitary pathology. (-) is used for patients
with wild-type AIP. Subjects marked with (?) did not undergo genetic analysis but had no clinical signs of pituitary disease. Subjects
with AIP mutation and elevated insulin-like growth factor-1 levels are shown by a symbol with a filled upper right corner, and an AIP-
mutation positive girl with premature telarche, ovarian enlargement and advanced bone age is indicated by a symbol with a filled
lower left corner. Adapted by the author Naves LA (39).
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39examination should be performed for exclusion of extra-
pituitary pathology that may imply syndromic disease, and
a comprehensive family history taken before referring
patients to genetic screening. Genetic testing in relatives
of patients with AIP mutations can be especially beneficial
in terms of early diagnosis, which may yield better out-
comes from treatment. Although no consensus proto-
cols for management of patients with AIP-mutated FIPA
currently exist, it may be appropriate to start regular
magnetic resonance imaging monitoring and hormonal
evaluation from early childhood because macroadenomas
and gigantism have been diagnosed in patients as young as
6–8 years (34,36). Widespread screening for AIP mutations
among apparently sporadic pituitary adenomas may not be
warranted, as the prevalence of AIP alterations is low in
such populations. However, AIP mutations are discovered
in approximately 12% of young patients (aged ,30 years)
and in 20% of pediatric patients, most often presenting
with growth hormone-secreting or prolactin-secreting mac-
roadenomas, suggesting that focused screening in this
patient group may provide valuable clinical information
(33,40).
The definition of FIPA has further widened the spectrum
of familial pituitary pathology in addition to the well-
known MEN 1 and Carney complex. The identification of
the AIP gene as a causative factor in a subset of patients
with FIPA has also provided some new insights into
pituitary tumorigenesis. Genetic testing can now be offered
to at-risk subjects in affected families, allowing for earlier
diagnosis and more successful treatment. Consensus guide-
lines concerning the management and follow-up of patients
with FIPA will hopefully be developed with the accumula-
tion of data from large international cohorts and long-term
monitoring studies. However, much remains to be done, as
the low prevalence and the uncertain penetrance of AIP
mutations suggests that other predisposing or modifying
genes are to be expected. It is also unclear whether patients
with FIPA additionally have a predisposition for other
endocrine or non-endocrine tumors, which could expand its
definition beyond the pituitary. Further studies will help to
clarify these issues and provide more information on the
genetic and molecular basis for the development of pituitary
adenomas.
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